1 Management of HIV and TB Co-infection in South Africa Halima Dawood Department of Medicine
2 Case Report 39 yr old female Referred to clinic on 14/06/2006 for consideration to commence antiretroviral therapy Diagnosed with pulmonary tuberculosis (smear +ve) at local clinic (10/03/2006) Good adherence to antituberculosis therapy Currently on maintenance phase: Rifinah 2 daily (isoniazid/rifampicin)
3 BACKGROUND HISTORY Diagnosed: HIV: Jan 2001 (at local clinic) No previous admissions to hospital No other past medical history Two children aged 17 and 13 yr both well Husband died in 2001 (AIDS related illness)
4 GENERAL EXAMINATION No symptoms on history/enquiry Mild temporal muscle wasting. No significant lymphadenopathy. Oral thrush. No melanonychia PR 80 /min BP 110/70 RR 14/min Apyrexial
5 Systemic Examination Cardiovascular System Normal Respiratory System Normal Abdomen Normal Central Nervous System Normal
6 ASSESSMENT 39 year old female with HIV infection, on maintenance phase of tuberculosis treatment with oral candidiasis World Health Organisation stage 3 HIV infection
8 Final Assessment 39 year old female on maintenance phase of tuberculosis treatment CD4 count = 79 cells/µl (AIDS) Medically suitable for antiretroviral roll-out programme Requires social/adherence counselling and ARV education
9 MANAGEMENT Assessed by multi-disciplinary team and found suitable for antiretroviral therapy Started regimen 1a :stavudine 40 mg bd lamivudine 150 mg bd efavirenz 600mg daily on 14/07/2006 whilst on maintenance phase of tuberculosis treatment
10 Management of HIV and TB Co-infection in South Africa
11 Introduction > 70% of 40 million HIV-1 infected people worldwide live in sub-saharan Africa high proportion are infected with tuberculosis Tuberculosis : leading cause of morbidity and mortality in this sub-group Highly active anti-retroviral treatment (HAART): reduced the incidence of HIV-1-associated-tuberculosis by more than 80% in some studies * * Lancet 2002: 359:
12 IMPACT OF HIV ON MTB HIV negative:10% infected with TB bacilli develop active TB during lifetime. HIV positive: 50% develop TB. TB occurs at any time in the course of HIV,usually early.
13 IMPACT OF HIV ON TB Progression to Disease:TB accelerates HIV disease Infectious Pool: MDR TB TB associated with decreased survival in HIV: Immune activation, Expression of cytokines, Increased viral replication (viral load fold increase with active TB)* *J Immunol 1996;157:1271
14 IMPACT OF MTB ON HIV Acceleration to AIDS Increases vertical transmission of HIV and increased congenital transmission of TB
15 How Does HIV Affect The Clinical Presentation Of TB? Unchanged (TBM, TB osteitis) Certain peculiar TB syndromes: - Pulmonary Syndrome - Lymphadenopathy Syndrome - Serositis Syndrome - Constitutional Syndrome Increased incidence of extra-pulmonary TB
16 DRUG METABOLISM INTERACTIONS (PHARMACOKINETIC)
17 RIFAMPICIN Significant pharmokinetic drug interactions: standard tuberculosis treatment + ARVs Rifampicin( rifamycin): potent inducer of cytochrome P450 enzyme system, iso-enzyme CYP3A4
18 RIFAMPICIN Rifampicin: metabolism + plasma levels of hepatically metabolised drugs: NNRTIs PIs decreased plasma levels may result in antiretroviral treatment failure HIV-infected patients treated with rifamycin- sparing regimens need prolonged streptomycin-based treatment: 9-12 months to prevent relapse
19 RIFABUTIN CDC: rifabutin instead of rifampicin for patients taking PIs or NNRTIs Rifabutin: weaker enzyme inducer than rifampicin but unavailable in state sector antiretroviral regimen - modified to make it compatible with standard, rifampicin-based tuberculosis treatment
20 Interactions with NNRTIs NNRTI levels reduced when given with rifampicin Area under curve of efavirenz is reduced by 22% and nevaripine by 37-58% * Trough levels of efavirenz and nevirapine remain therapeutic but are reduced CDC recommends:increasing efavirenz dose to 800mg daily *Southern African Journal of HIV Medicine 2004: March: 28-32
21 Interactions with NNRTIs Population pharmacokinetic study of efavirenz: hepatic clearance was 28% higher in white non-hispanics than in African-Americans and Hispanics * Major ethnic differences exist in allellic variations of iso-enzyme CYP2B6 which is mainly responsible for metabolizing efavirenz * Antimicrobial Agents Chemotherapy 2003; 47:
22 Interactions with NNRTIs SA guidelines do not recommend increasing efavirenz dose when co-administered with rifampicin, due to increased risk of toxicity no published data on efavirenz metabolism in the South African population Nevirapine clearance also varies between ethnic groups * Standard doses of nevirapine are effective when coadministered with rifampicin * Br J Clin Pharmacology 2004: 54 ;
23 Role of PIs Most PI levels significantly when co-administered with rifampicin and should not be used, except ritonavir. ritonavir 400mg bd to overcomes the enzyme induction Ritonavir : GI intolerance - improved by gradual dose escalation over one week
24 Interactions with NRTIs 3 NRTIs regimens were previously recommended due to no significant interactions with rifampicin. Recent studies : these regimens are inferior to conventional NNRTI/PI regimens * 3 NRTIs are no longer recommended *South. African Journal of HIV Medicine 2004: 14: 28-35
25 SA Recommendations for Co-administering PI + NNRTIs + Rifampicin
26 Single PIs ritonavir Amprenavir Indinavir Nelfinavir Saquinavir Dose when combined with rifampicin 600mg 12hrly Rifampicin should not be used together with these single PIs comments poorly tolerated in adults:gi side effects. Not used as single agent Change the regimen to make it compatible with rifampicin (do not use a drug that the patient has previously failed)
27 Boosted PI Combinations Dose when combined with rifampicin Comments Saquinavir/ ritonavir Lopinavir/ ritonavir Saquinavir 400mg plus ritonavir 400mg 12hrly Kaletra 400mg/ 100mg plus Ritonavir 300mg 12hrly Limited clinical experience Limited clinical experience
28 NNRTIs Efavirenz Nevirapine Dose when combined with rifampicin 600mg daily 200mg twice daily Comments CDC guidelines recommend 800mg but efavirenz metabolism is slower in Afro-Americans and increased CNS side effects may occur Possible increased risk of hepatotoxicity, particularly during the 1 st two months of nevirapine-containing antiretroviral therapy
29 Pharmacodynamic Interactions Additive risk of side-effects and drug toxicity when antiretrovirals combined with TB Rx Pyridoxine : give to all HIV-infected patients to reduce the risk of INH-induced peripheral neuropathy Alcohol excess: increased risk of hepatotoxicity and peripheral neuropathy,counsel regarding alcohol discontinuation
30 Common Causes of Shared Side-effects of Antituberculous and Antiretroviral therapy
32 Management of HIV-infected Patients diagnosed with active tuberculosis when taking antiretroviral therapy : SA National Guidelines
33 Currently on HAART and develop TB continue HAART throughout standard tuberculosis treatment, with changes where necessary, to the patient s antiretroviral treatment regimen.
34 The recommended regimen for antiretroviral-naïve patients in the public sector: Regimen 1 1. Stavudine (d4t) 40 mg every 12hrs (or 30mg every 12hrs if <60mg), plus 2. Lamivudine (3TC) 150mg 12hrly, plus 3. Either efavirenz (EFV) 600mg nocte (or 400mg if < 40kg) or nevirapine (NVP) 200mg daily for 2 weeks, followed by 200mg every 12 hrs. Efavirenz is teratogenic, hence women of childbearing potential who want to fall pregnant are treated with nevirapine
35 Develop tuberculosis while taking NNRTI If on efavirenz continue antiretroviral therapy unchanged whilst on anti-tuberculosis treatment. If stable (preferably > 2 months) on nevirapine, when tuberculosis develops, the regimen can be continued. Nevirapine can also be changed to efavirenz, as the interaction between efavirenz and rifampicin is less marked.
36 Patients treated concomitantly with nevirapine and rifampicin should be carefully monitored for hepatotoxicity Transaminase levels should be checked every month
37 REGIMEN 2 Fail regimen 1: commence on PI based second-line antiretroviral therapy as follows: 1. Didanosine (ddi) 400mg once a day (250mg daily if < 60kg), plus 2. Zidovudine (AZT) 300mg 12 hourly plus, 3. Lopinavir/ritonavir (LPV/r) 400/100mg every 12 hours
38 If tuberculosis is diagnosed in a patient taking the second-line treatment regimen, ritonavir 300mg twice daily should be added to the regimen. When rifampicin is stopped, it takes two weeks before the cytochrome P450 iso-enzyme induction is reversed. Thus, the added ritonavir should only be stopped 2 weeks after completion of tuberculosis treatment.
39 Management of HIV-infected patients diagnosed with active tuberculosis and not yet taking ARV therapy
40 Estimated that > 50% of new adult cases of tuberculosis in South Africa are co-infected with HIV Majority patients are not on ARV therapy, and many do not fulfil clinical criteria for ARV therapy initiation Clinical criteria for initiation of ARV therapy are as follows:
41 Antiretroviral Therapy for Individuals with Tuberculosis Co-infection Situation Pulmonary TB and CD4 count < 50/mm 3 or extrapulmonary TB Recommendations Start TB therapy. Start ARVs as soon as TB therapy is tolerated: regimen 1a Pulmonary TB and CD /mm 3 or total lymphocyte count /mm 3 Start TB therapy. Start ARV regimen after 2 months of TB therapy: Pulmonary TB and CD4 >200/mm 3 or total lymphocyte count > /mm 3 Treat TB. Monitor CD4 counts if available. Start ART according to ART Guidelines
42 World Health Organization (WHO) stage 4 disease (AIDS) or CD4 < 200 cells/µl. Extrapulmonary TB, although a stage 4 defining illness, is not a criterion for initiating ARV therapy unless CD4 count < 200 cells/µl. If no history of stage 4 illness and CD4 count > 200 cells/ul, antiretroviral therapy is not indicated. Need for antiretrovirals should be reassessed on completion of tuberculosis treatment
43 If ARVs indicated, 2 months of anti-tuberculosis therapy completed before starting ARVs, due to the risks of additive side-effects and drug toxicity. If CD4 < 50 cells/µl or other serious HIV-related illness exists, ARVs started from 2 weeks. In this setting, first ensure that the patient is tolerating tuberculosis treatment and responding to it.
44 Often difficult to establish patient readiness for antiretrovirals within 2 weeks. Patients should be started on 1st-line agents consisting of stavudine, lamivudine and efavirenz. Initiation of nevirapine during tuberculosis should be avoided because of limited experience and danger of shared hepatotoxicity.
45 MULTI-DRUG RESISITANT TUBERCULOSIS All HIV-infected patients with multi-drug resistant tuberculosis should be considered for antiretroviral therapy, even if CD4 >200 cells/ul, since prognosis is poor. Poor adherence and substance abuse must be excluded before starting antiretroviral therapy
46 MULTI-DRUG RESISITANT TUBERCULOSIS Intensive adherence support is needed in treating these patients. Shared side-effects and potential drug interactions between antiretrovirals and drugs used to treat multi-drug resisitant tuberculosis.
47 ADHERENCE Patients taking both antiretrovirals and anti-tuberculosis treatment are required to take large numbers of tablets daily. develop side-effects :GI intolerance - make treatment adherence difficult. Intensive adherence support is needed.
48 ADHERENCE Side-effects that impact on adherence e.g nausea, should be actively managed. If side-effects or pill burden cannot be tolerated, antiretroviral treatment interruption for the duration of tuberculosis treatment may be considered.
50 IMMUNE RECONSTITUTION Advanced HIV disease (CD4 <50 cells/ul) :immune reconstitution syndrome during the first few months of antiretroviral therapy. Improving immune function may cause paradoxical deterioration of an opportunistic infection being treated or unmask a previously occult one.
51 Immune reconstitution syndrome Clinical presentation: fevers lymphadenopathy worsening pulmonary lesions expanding lesions of the central nervous system
52 Management of Immune Reconstitution Syndrome Role of corticosteroids unclear : consider for severe reactions Reactions are self-limiting although they may require a brief course of corticosteroids to reduce inflammation of CNS or severe respiratory symptoms
53 IMMUNE RECONSTITUTION Not indicative of treatment failure or a drug side-effect. ART should not be interrupted or changed if immune reconstitution syndrome occurs
54 AREAS FOR FUTURE RESEARCH Current knowledge of antiretroviral interactions with antituberculosis therapy is based on small studies and case reports. Evidence exists of genetic variability in metabolism of nevirapine and efavirenz, the clinical significance of which is unclear.
55 AREAS FOR FUTURE RESEARCH Need for pharmaco-epidemiological studies to assess frequency and severity of shared side-effects. Optimal timing of initiating antiretroviral therapy in patients with tuberculosis can only be addressed in a randomized controlled trial.
Guideline Treatment of tuberculosis in patients with HIV co-infection Version 3.0 Key critical points Co-infection with Tuberculosis (TB) and HIV is common in many parts of the world, especially sub-saharan
GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS IN SOUTH AFRICA 2010 1 TB prophylaxis GUIDELINES FOR TUBERCULOSIS PREVENTIVE THERAPY AMONG HIV INFECTED INDIVIDUALS Background
Medical Journal of Therapeutics Africa 2007 Vol 1, No 2 Page 148 SUMMARY OF GUIDELINES FOR THE USE OF ANTIRETROVIRAL AGENTS IN HIV-INFECTED ADULTS AND ADOLESCENTS. MM Thorell PhD University of the Sciences
Antiretroviral therapy for HIV infection in infants and children: Towards universal access Executive summary of recommendations Preliminary version for program planning 2010 Executive summary Tremendous
143 Chapter 10 Human Immuno Deficiency Virus Infection Chapter 10 Human Immuno Deficiency Virus Infection...143 HIV infection...144 Clinical Features...146 Clinical Staging of HIV infection recommended
TREATMENT FAILURE AND PATTERNS OF GENOTYPIC DRUG RESISTANCE MUTATIONS AMONG HAART EXPERIENCED HIV-1 PATIENTS AT KCMC Theonest Ndyetabura KILIMANJARO CHRISTIAN MEDICAL CENTRE / KILIMANJARO CLINICAL RESERCH
Combination Anti-Retroviral Therapy (CART) - Rationale and Recommendation M Dinaker INTRODUCTION The wide availability of effective, safe and mostly well tolerated combined anti-retroviral therapy (CART)
Chapter 3 South African guidelines and introduction to clinical cases 3.1. South African national antiretroviral guidelines When this book was published in 2012 the current national antiretroviral treatment
Southern African HIV Clinicians Society Clinical Guidelines Antiretroviral therapy in adults Introduction The magnitude of HIV infection in Southern African and the number of impoverished people who desperately
HIV Medicine (2005), 6 (Suppl. 2), 62 83 r 2005 British HIV Association BHIVA treatment guidelines for tuberculosis (TB)/HIV infection 2005 AL Pozniak, 1 RF Miller, 2 MCI Lipman, 3 AR Freedman, 4 LP Ormerod,
THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2013 VERSION 14 March 2013 Contents Acronym glossary... 2 1. Goals of the programme... 3 2. Objectives... 3 3. Specific Objectives... 3 4. Adults and
TB & HIV co infection interactions, considerations, pitfalls Dr Sindisiwe van Zyl Background facing a double epidemic TB leads to HIV disease progression & vice versa 70% TB patients are HIV co infected
TB-HIV Co-Infection in Children Reené Naidoo Paediatric HIV/TB Symposium August 2013 Introduction TB & HIV are two of the leading causes of morbidity & mortality in children in South Africa HIV infection
Tuberculosis: prevention, diagnosis, management and service organisation Review questions Number A B C D E F G H I J Review question What are the most effective methods for i) sputum smear microscopy and
Chapter Four: Treatment of Tuberculosis Disease The standard of tuberculosis (TB) treatment in Los Angeles County (LAC) is to initiate an appropriate chemotherapeutic regimen along with Directly Observed
Current Standards of Care for HIV-TB some clinical issues OPEN FORUM Conference ADDIS ABABA August 2010 Dr. Tony Moll, Rural Clinician, Tugela Ferry, KZN, South Africa Goal of TB & HIV Collaborative Activities
DIAGNOSIS AND TREATMENT OF TUBERCULOSIS James Sunstrum, M.D. Beaumont Health 2014 MFMER slide-1 Disclosure and Objectives Disclosure: No conflicts of interest =============================== Objectives
Challenges of TB in the HIVinfected child CORE Group SOTA Douglas Watson, M.D. University of Maryland, Baltimore 6 October 2009 Challenges of TB in the HIVinfected child Epidemiology: Common, but incidence
International AIDS Society USA Topics in HIV Medicine Perspective Tuberculosis and HIV in the Caribbean: Approaches to Diagnosis, Treatment, and Prophylaxis In the Caribbean region, the lifetime risk of
British HIV Association guidelines for the treatment of TB/ HIV co-infection 2009 AL Pozniak, S Collins, KM Coyne, AR Freedman, MA Johnson, MCI Lipman, SB Lucas, RF Miller and LP Ormerod, and on behalf
International AIDS Society - Industry Liaison Forum Meeting 5 March 2012 Treating HIV in children with tuberculosis Helen McIlleron, Division of Clinical Pharmacology University of Cape Town Challenges
Scott M. Hammer Antiretroviral Therapy I. Introduction The field of antiretroviral therapy has been explosive over the past 17 years as HIV targets have been identified, drugs developed and pathogenesis
MANAGEMENT OF TUBERCULOSIS Dean B. Ellithorpe, M.D. Clinical Professor of Medicine Section of Pulmonary Diseases, Critical Care and Environmental Medicine Tulane University School of Medicine INTRODUCTION
TB Prevention, Diagnosis and Treatment Accelerating advocacy on TB/HIV 15th July, Vienna Diagnosis Microscopy of specially stained sputum is the main test for diagnosing TB (1 2 days) TB bacilli seen in
London Therapeutic Tender Implementation: Guidance for Clinical Use 4 th June 2014 FINAL Contents 3. General principles 4. Financial impact of therapeutic tendering for branded ARVs 5. London ARV algorithm:
Module 3 TREATMENT OF CHILDHOOD TB Burden of TB in children Tuberculosis (TB) in children is common wherever TB is common in adults i.e. TB endemic settings TB is an important cause of illness and death
HIV/AIDS Treatment Information Service 1 800 HIV 0440 HIV and Its Treatment What You Should Know 2nd edition HIV/AIDS TREATMENT INFORMATION SERVICE 2nd Edition HIV and Its Treatment: What You Should Know
AMBULATORY TREATMENT AND PUBLIC HEALTH MEASURES FOR A PATIENT WITH UNCOMPLICATED PULMONARY TUBERCULOSIS (UPDATE 2004) Internal guidelines of the Tuberculosis & Chest Service of the Department of Health
TB Intensive San Antonio, Texas November 11 14, 2014 TB in the HIV Patient Lisa Armitige, MD, PhD November 13, 2014 Lisa Armitige, MD, PhD has the following disclosures to make: No conflict of interests
FOR YOUR PATIENTS WITH RELAPSING FORMS OF MS INITIATING ORAL AUBAGIO (teriflunomide) THERAPY WARNING: HEPATOTOXICITY AND RISK OF TERATOGENICITY Severe liver injury including fatal liver failure has been
Contents I. Epidemiology of TB, TB/HIV/AIDS and reciprocal influence of TB and HIV... 135 1. Epidemiology of TB... 135 2. Epidemiology of TB/HIV coinfection... 135 3. Reciprocal influence of HIV and TB...
Overview of Tuberculosis Epidemiology, Transmission, Clinical Presentation, and Treatment Tuberculosis Airborne disease caused by the bacterium Mycobacterium tuberculosis (M. tb) M. tb complex (MTBC) includes
HIV Drug Resistance in the Asia- Pacific David A Cooper National Centre in HIV Epidemiology and Clinical Research The University of New South Wales Sydney, Australia HIVDR in Asia Pacific Transmitted resistance
ANTIRETROVIRAL TREATMENT What is ART and ARV? ART is a short form for Antiretroviral Therapy (or Treatment). Antiretroviral therapy is a treatment consisting of a combination of drugs which work against
DOI: 10.1111/j.1468-1293.2011.00954.x r 2011 British HIV Association HIV Medicine (2011), 12, 517 524 BRITISH HIV ASSOCIATION GUIDELINES British HIV Association guidelines for the treatment of TB/HIV coinfection
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Acute Side Effects from Antiretroviral Medication David M. Hachey, Pharm.D., BCPS, AAHIVP Clinical Professor Idaho State University Presentation prepared by:
Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline
abacavir, zidovudine, lamivudine: 1 abacavir, zidovudine and lamivudine fixed dose combination for first line treatment of HIV infection Abacavir/AZT/3TC is a fixed dose combination of three drugs recommended
Guideline Treatment of tuberculosis in pregnant women and newborn infants Version 3.0 Key critical points The decision to treat tuberculosis (TB) in pregnancy must consider the potential risks to mother
MODULE THREE TB Treatment Treatment Action Group TB/HIV Advocacy Toolkit 1 Topics to be covered TB treatment fundamentals Treatment of TB infection and disease TB treatment research Advocacy issues 2 Section
Guideline Treatment of tuberculosis in renal disease Version 3.0 Key critical points Renal failure is recognised as a risk factor for developing tuberculosis. Renal failure is recognised as a risk factor
Slide 1 Cryptococcal Screening Program Case Studies Image courtesy of World Health Organization National Center for Emerging and Zoonotic Infectious Diseases Mycotic Diseases Branch Slide 2 Note to trainers
Paediatric HIV treatment update James Nuttall Red Cross War Memorial Children s Hospital & University of Cape Town ART Resistance & New Treatment Options 6 th FIDSSA Conference, 5-7 November 2015 ART Eligibility
City and County of San Francisco Department of Public Health Tuberculosis Control Unit Julie Higashi, MD, PhD Director Population Health Division Edwin M. Lee Mayor Disease Prevention and Control Branch
Self-Study Modules on Tuberculosis Treatment of Latent Tuberculosis Infection and Tube rc ulos is Disease U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention National
QUICK REFERENCE FOR HEALTHCARE PROVIDERS Ministry of Health Malaysia Academy of Medicine Malaysia Malaysian Thoracic Society KEY MESSAGES 1. Tuberculosis (TB) is a notifiable infectious disease. Timely
MANAGEMENT OF COMMON SIDE EFFECTS of INH (Isoniazid), RIF (Rifampin), PZA (Pyrazinamide), and EMB (Ethambutol) 1. Hepatotoxicity: In Active TB Disease a. Background: 1. Among the 4 standard anti-tb drugs,
Safety and Efficacy of DAA + PR in HCV/HIV co-infected patients Mark Sulkowski, MD Johns Hopkins University Baltimore Maryland USA Liver disease is the second leading cause of death amongst HIV-positive
Recent Advances in The Treatment of Mycobacterium Tuberculosis Dr Mohd Arif Mohd Zim Senior Lecturer & Respiratory Physician Faculty of Medicine, Universiti Teknologi MARA firstname.lastname@example.org
TUBERCULOSIS SCREENING AND TREATMENT IN PREGNANCY Stephanie N. Lin MD 2/12/2016 Epidemiology of TB 9.6 million new cases in 2014 12% of them are in HIV positive patients 1.5 million deaths in 2014 ~646
Regulatory Approach in Germany and in the EU to Fixed Dose Combination Medicinal Products Using HIV/AIDS Treatment as an Example Prof. Dr. rer. nat. habil. Harald G. Schweim President Federal Institute
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Updated HIV Treatment Guidelines 2014 Brian R. Wood, MD Assistant Professor of Medicine, University of Washington Medical Director, NW AETC ECHO Last Updated:
Chapter 1 Overview of Tuberculosis Epidemiology in the United States Table of Contents Chapter Objectives.... 1 Progress Toward TB Elimination in the United States.... 3 TB Disease Trends in the United
HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf
Tuberculosis: An Overview By: Raymond Lengel, FNP, MSN, RN Purpose: To provide an overview of tuberculosis including its transmission, risk factors, signs and symptoms, diagnosis and treatment options.
Revised National Tuberculosis Control Programme (RNTCP) Dr. NAVPREET Assistant Prof., Deptt. of Community Medicine GMCH Chandigarh Problem Statement of TB in India India accounts for nearly 1/4 th of global
5.1 Types of Medications Nucleoside, Nucleotide & Non-Nucleoside Reverse-Transcriptase Inhibitors (NRTI, NtRTI and NNRTI) HIV is a single stranded RNA virus. In order to make more copies of itself in a
Antiretroviral Treatment Michael A. Tolle, MD, MPH Heidi Schwarzwald, MD, MPH Nancy R. Calles, MSN, PNP, ACRN, MPH Objectives 1. Discuss the goals of treatment for human immunodeficiency virus (HIV) infection.
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.07.09 Subject: Aubagio Page: 1 of 6 Last Review Date: December 5, 2014 Aubagio Description Aubagio (teriflunomide)
HCV/HIVCo-infection A case study by Dominic Côté, Nurse Clinician B.Sc Chronic Viral Illness Services McGill University Health Centre Objectives By sharing a case study of a patient co-infected with HIV/HCV
1 Treat for AIDS There are now medicines which can treat AIDS. They are called antiretrovirals, or ARVs for short. ARVs do not cure HIV! But they can stop a person with HIV from dying of AIDS. ARVs only
Chapter 36 Media Directory Drugs for Viral Infections Slide 23 Slide 27 Slide 29 Zidovudine Animation Saquinavir Mesylate Animation Acyclovir Animation Upper Saddle River, New Jersey 07458 All rights reserved.
Paediatric ARV Procurement Working Group and Coordinated Procurement Product Optimization around the IATT optimized formulations and supporting new product introductions Discussion Points Switch to optimal
FARMACI, INNOVAZIONE e INFEZIONE DA HIV / AIDS Stefano Vella Dipartimento del Farmaco Istituto Superiore di Sanità - Roma Stages of HIV-1 Life Cycle Targeted by Anti-HIV Drugs In: Gulick RM, Topics HIV
New York City Department of Health Protocols for Latent TB Infection Treatment CONTENT A. Medical evaluation for latent TB infection (LTBI) treatment 1. Medical history and physical examination 2. Chest
Tuberculousmeningitis: what is the best treatment regimen? H S Schaaf Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of Medicine and Health Sciences, Stellenbosch University
Generic antiretrovirals in Europe: a blessing or a curse? Ricardo Jorge Camacho 1 Molecular Biology Laboratory, Centro Hospitalar de Lisboa Ocidental 2 Instituto de Higiene e Medicina Tropical, Universidade
TB conference, 10-13 June 2014, Durban, South Africa Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection Dr Augustin Ntilivamunda Objectives of 2013 WHO
HBV screening and management in HIV-infected children and adolescents Linda Aurpibul M.D. Research Institute for Health Sciences, Chiang Mai University 8% HIV and Hepatitis B Co-infection Among Perinatally
Guideline Treatment of tuberculosis in adults and children Version 2.1 July 2015 Contents What this guideline covers:... 1 What this guideline does not cover:... 1 Standard regimens for pulmonary tuberculosis...
Antiretroviral Therapy Adult ART Table 1. When to Start Therapy* Clinical Category CD4+ Count Viral Load Recommendation Symptomatic (AIDS or severe symptoms) Any value Any value Treat Asymptomatic, AIDS
NORTHWEST AIDS EDUCATION AND TRAINING CENTER HIV 201: What I Wish I Knew as a NEW RN Andrea Carriedo, RN The New Hope Clinic NO CONFLICTS OF INEREST OR RELATIONSHIPS TO DISCLOSE Objectives Describe the
Guidelines f the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents Visit the AIDSinfo website to access the most up-to-date guideline. Register f e-mail notification of guideline updates
ISPUB.COM The Internet Journal of Infectious Diseases Volume 6 Number 2 Clinical response to Highly Active Antiretroviral Treatment (HAART) in a patient with Kaposi's sarcoma: A case presentation Y Graza,
Vol 1 October 2009 Clinical Pharmacist 393 Since the advent of combination antiretroviral therapy in the mid-1990s HIV-infected individuals are now living longer with improved quality of life. Medication
DIAGNOSIS AND MANAGEMENT OF TUBERCULOSIS The HIV epidemic has greatly increased the incidence of tuberculosis (TB) and complicated TB diagnosis: smear-negative pulmonary TB and extrapulmonary TB account
Protocol Effective Date: 01 July 2013 Review Date: 01 July 2016 Supersedes: New Protocol Health Service Directive Tuberculosis Management Protocol for the Treatment of Tuberculosis 1. Purpose This protocol
Bioequivalence Study Design Considerations Dr. John Gordon Key Output of Programme A list of prequalified medicinal products used for treatment of HIV/AIDS, malaria, tuberculosis, influenza, and for reproductive
ANTI-RETROVIRAL THERAPY OF HIV INFECTED PATIENTS Lubis R 1, Bulgiba AM 2 1 Department of Epidemiology, Faculty of Public Health, University of Sumatera Utara, Medan, Indonesia 2 Julius Centre University
HIV 1 A reference guide for prescription HIV-1 medications Several different kinds of antiretroviral drugs are currently used to treat HIV-1 infection. These medicines are the ones most commonly used in
Treatment of TB Disease The Basics Jennifer Whitaker, MD, MS Tuberculosis Clinical Intensive Program, Mayo Clinic, Rochester November 19, 2013 2013 MFMER slide-1 Disclosures Pfizer Educational Grant for
Understanding Pharmacokinetic Variability and Managing Drug Interactions Courtney V. Fletcher, Pharm.D. Dean, College of Pharmacy Professor, Department of Pharmacy Practice and Division of Infectious Diseases
Tuberculosis in Pregnant versus non- Tuberculosis in Pregnancy Mark J. Granada, MD Means of Spreading TB bacilli Coughing Sneezing Singing Spitting Laughing Rarely, pregnant TB patient may pass TB to unborn